SCM
ALNY icon

Suffolk Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Suffolk Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-114,244
Closed -$9.11M – 123
2017
Q2 		$9.11M Sell
114,244
-7,287
-6% -$466K 1.2% 40
2017
Q1 		$6.23M Buy
+121,531
New +$5.62M 0.83% 47

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Suffolk Capital Management's ALNY Position: Q3 2017 in Review

Suffolk Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2017, closing a stake of 114,244 shares — an estimated $9.11M sold.

Suffolk Capital Management first reported a position in ALNY in Q1 2017 and held it in 2 quarters. The position peaked at $9.11M in Q2 2017. 236 funds tracked by Wall St. Rank hold ALNY as of Q3 2017.

  • Suffolk Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Suffolk Capital Management sold 114,244 Alnylam Pharmaceuticals shares in Q3 2017, an estimated $9.11M.
  • Suffolk Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Suffolk Capital Management's Alnylam Pharmaceuticals position peaked at $9.11M in Q2 2017.
  • 236 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2017.

Based on Suffolk Capital Management's 13F filing for Q3 2017, filed 3 Nov 2017.